JAZZ
Jazz Pharmaceuticals
Is JAZZ Halal?
Biopharmaceuticals for sleep and oncology with permissible business.
What You Should Know
Jazz develops medicines for sleep disorders, epilepsy, and cancer. Its March 31, 2026 Form 10-Q reports $11,859.6 million of assets, $5,354.7 million of interest-bearing debt, $1,844.3 million of cash, $836.3 million of receivables and $1,068.9 million of quarterly revenue. Debt/assets is 45.15%, above the examined FTSE, MSCI and Malaysia asset limits; disclosed interest income from available-for-sale securities is 2.19% of revenue. The core pharmaceutical activity remains generally permissible, while controlled-substance, ingredient and patient-use questions require qualitative review.
⚠️ Concerns
- •High acquisition-related debt
- •Controlled-substance and patient-use questions
- •Product ingredients and specialty-pharma licensing
- •Interest income
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
5,354.7 / 11,859.6
2,874.3 / 11,859.6
2,680.6 / 11,859.6
23.4 / 1,068.9
- Financial
- Fails
- Overall
- Fails
Debt/assets is 45.15%, above the examined FTSE 33.333% limit; liquidity/assets is 24.24%, receivables-plus-cash/assets is 22.61% and disclosed interest income is 2.19% of revenue.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 45.15%, above the examined MSCI 33.33% total-assets limit; the other examined ratios are below their limits.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 45.15%, above the examined Malaysia 33% limit; this is a calculation against the named ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; the debt screen fails independently.
Business-activity disclosure
Jazz Pharmaceuticals develops and commercializes specialty medicines for sleep disorders, oncology and other diseases. The core pharmaceutical activity is generally permissible.
Limitation: The filing does not allocate every product, ingredient, controlled-substance, licensing or patient end use into a scholar-approved prohibited-revenue numerator.
Purification
Jazz discloses $23.4 million of interest income from available-for-sale securities but does not provide a scholar-approved purification percentage or separate prohibited-activity numerator.
Inputs, assumptions and primary sources
- Amounts are USD millions from Jazz Pharmaceuticals' March 31, 2026 Form 10-Q.
- Interest-bearing debt includes $1,030.5 million of current portion and $4,324.2 million of long-term debt; operating leases are excluded.
- Cash is $1,844.3 million and time-deposit investments are $1,030.0 million; the investments are used as the interest-bearing-securities proxy.
- Accounts receivable are $836.3 million net; first-quarter total revenues are $1,068.9 million.
- Interest income from available-for-sale securities is $23.4 million and is used as the disclosed-income proxy.
- Specialty pharmaceuticals for sleep disorders, oncology and other diseases are treated as generally permissible, while controlled-substance, ingredient, marketing and patient-use questions require qualitative review.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →